Drug Trial Radar · NCT01500278
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate
Last checked: Nov 20, 2026Latest source record: Jul 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
915
Actual
Start
Dec 2011
Primary completion
Nov 2015
Study completion Jan 2016
Sponsor
- Lead sponsor
- UCB Pharma SAUCB
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Dec 28, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is conducted to evaluate the short (12 Weeks) and long term (104 Weeks) efficacy of Certolizumab Pegol compared with Adalimumab both in combination with Methotrexate (MTX) in the treatment of moderate to severe Rheumatoid Arthritis (RA) that is not responding adequately to MTX.
Conditions
- Rheumatoid Arthritis
Interventions
Certolizumab Pegol (CZP)Biological
* Active substance: an injectable volume of 1 ml solution for injection CZP * Pharmaceutical form: prefilled syringes CZP * Concentration: 200 mg/ml CZP * Route of Administration: injections will be given subcutaneously: loading dose of CZP 400 mg at Baseline, and Weeks 2 and 4, followed by a maintenance dose of 200 mg every 2 weeks through Week 102 or withdrawal.
Adalimumab (ADA)Biological
* Active substance: an injectable volume of 0.8 ml solution for injection ADA * Pharmaceutical form: prefilled syringes ADA * Concentration: 40 mg/0.8 ml ADA * Route of Administration: injections will be given subcutaneously. ADA 40 mg plus an injection with Placebo (to preserve blind) at Baseline, and Weeks 2 and 4, followed by ADA 40 mg every 2 weeks through Week 102 or withdrawal.
Methotrexate (MTX)Drug
* Active substance: Methotrexate * Pharmaceutical form: oral tablet * Concentration: 15-25 mg/week * Route of Administration: MTX orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects Who Met the American College of Rheumatology 20 % (ACR20) Criteria at Week 12Time frame: Week 12
- Percentage of Subjects Who Had a Disease Activity Score 28 [Erythrocyte Sedimentation Rate] (DAS28 [ESR]) ≤ 3.2 at Week 104Time frame: Week 104
Locations
175 sites in 20 countries. Site status is shown where the registry gives one.
141
Birmingham, Alabama
214
Tuscaloosa, Alabama
159
Tucson, Arizona
152
Hot Springs, Arkansas
147
Covina, California
161
Fullerton, California
217
La Mesa, California
149
Los Angeles, California
144
Menifee, California
185
Roseville, California
208
Sacramento, California
189
Van Nuys, California
148
Whittier, California
220
Lewes, Delaware
142
Aventura, Florida
216
Fort Lauderdale, Florida
162
Gainesville, Florida
209
Vero Beach, Florida
145
Coeur d'Alene, Idaho
202
Maywood, Illinois
134
Lexington, Kentucky
178
Baltimore, Maryland
137
Battle Creek, Michigan
153
Detroit, Michigan
155
Lansing, Michigan
204
Eagan, Minnesota
180
Rochester, Minnesota
143
Saint Louis Park, Minnesota
135
Omaha, Nebraska
170
Reno, Nevada
201
Teaneck, New Jersey
150
Voorhees Township, New Jersey
205
Albuquerque, New Mexico
154
Albany, New York
136
Brooklyn, New York
219
Orchard Park, New York
207
Plainview, New York
167
Syracuse, New York
140
Cincinnati, Ohio
184
Oklahoma City, Oklahoma
Showing 40 of 175 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.